Skip to main content
. 2020 Nov 13;10(11):1552. doi: 10.3390/biom10111552

Figure 2.

Figure 2

Molecular design and coagulation studies: (A) PARIN5 is based on sequence homology with PAR1, which makes it recognized by thrombin. The molecule was modified with a tosyl group as a protective group at the N-terminal, and with chloro-methyl-ketone (CMK) as a serine active site blocker at the C-terminal. Coagulation studies (BD) were conducted to identify the optimal therapeutic window for PARIN5 treatment. Orange arrows correspond to treatment dosages.